Publication:
Circulating palmitoleic acid is associated with cerebral glucose metabolism in healthy middle-aged individuals: results from the Progression of Early Subclinical Atherosclerosis prospective cohort study.

dc.contributor.authorSala-Vila, Aleix
dc.contributor.authorTristão-Pereira, Catarina
dc.contributor.authorLázaro, Iolanda
dc.contributor.authorShekari, Mehrnaz
dc.contributor.authorFernández-Pena, Alberto
dc.contributor.authorMonereo-Sánchez, Jennifer
dc.contributor.authorGarcia-Lunar, Ines
dc.contributor.authorPerez-Herreras, Cristina
dc.contributor.authorMoro, Maria Angeles
dc.contributor.authorGarcia-Alvarez, Ana
dc.contributor.authorSanchez-Gonzalez, Javier
dc.contributor.authorGispert, Juan Domingo
dc.contributor.authorIbanez, Borja
dc.contributor.authorFuster, Valentin
dc.contributor.authorCortes-Canteli, Marta
dc.date.accessioned2026-11-06T16:26:07Z
dc.date.available2026-11-06T16:26:07Z
dc.date.issued2026-08
dc.description.abstractBACKGROUND: Excess energy intake upregulates de novo lipogenesis (DNL). Circulating palmitoleic acid (POA) is an objective DNL biomarker associated with higher cardiovascular risk, which has been linked to cerebral hypometabolism. Whether POA also relates to altered cerebral glucose metabolism in midlife remains unknown. OBJECTIVES: This study aimed to examine cross-sectional and longitudinal associations between circulating POA (predictor) and cerebral glucose hypometabolism (outcome), a neuroimaging marker linked to increased risk of subsequent cognitive decline. METHODS: We studied 461 middle-aged [median age, 51 (47-54) y] individuals with subclinical atherosclerosis from the Progression of Early Subclinical Atherosclerosis (PESA) study, a longitudinal observational cohort of asymptomatic individuals (NCT01410318). Red blood cell (RBC) POA was quantified by gas chromatography in blood samples collected at 2 visits of PESA participants who had undergone longitudinal cerebral F-fluorodeoxyglucose (FDG) positron emission tomography (4.9 y of follow-up time). Dietary data were derived from a validated food-frequency questionnaire. Associations were assessed using region-of-interest and voxelwise multiple regression models as well as mediation analysis. RESULTS: Cross-sectionally, higher RBC POA was associated with widespread lower FDG uptake across the brain [β = -0.119 (95% confidence interval: -0.206, -0.032), P = 0.007], even after adjusting for cardiovascular risk. Longitudinally, participants with sustained high RBC POA exhibited a 65% greater decline in cerebral FDG uptake compared with those with sustained low POA [β = -0.403 (-0.744, -0.063), P = 0.021], particularly in frontal and parietal regions. RBC POA proportions were higher among individuals adhering to the predefined "Social-Business" dietary pattern and were significantly associated with increased alcohol intake. Furthermore, the association between alcohol intake and subsequent precuneus hypometabolism was partially mediated by RBC POA proportions. CONCLUSIONS: RBC POA, a marker of DNL, is associated with cerebral glucose hypometabolism, supporting that healthy dietary habits in midlife are key to preserving brain health. This trial was registered at clinicaltrials.gov as NCT01410318.
dc.description.peerreviewedSí
dc.description.tableofcontentsThe Progression of Early Subclinical Atherosclerosis study is funded by the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and Santander Bank, and also receives funding from the European Regional Development Fund (ERDF - A Way to Build Europe) , and the European Social Fund (ESF - Investing in Your Future) . CNIC is a Severo Ochoa Center of Excellence (grant CEX2020-001041-S funded by MICIN/AEI/10.13039/501100011033) and is supported by the Carlos III Institute of Health (ISCIII) , the Ministry of Science and Innovation, and the Pro CNIC Foundation. AS-V was supported by ISCIII, through the project PI22/00071, co-funded by European Regional Development Fund " Investing in your future. " CT-P was supported by a " la Caixa " Foundation fellowship (LCF/BQ/DI19/11730052) . BI was supported by the European Commission (ERC-CoG 819775, and H2020-HEALTH 945118) , the Spanish Ministry of Science and Innovation (PID2019-110369RB-I00) , and the Community of Madrid (P2022/BMD-7403, RENIM-CM) . Acknowledgment is made to the Sephardic Foundation on Aging and other donors of the Alzheimer ' s Disease Research (Grant Number A2022034S) , a program of the BrightFocus Foundation, for the partial support of this research. This work was supported by the Cardiovascular Risk Factors and Brain Health Program at CNIC. The funding agencies had no role in the study design, data collection, analysis, decision to publish, or manuscript preparation.
dc.format.number2
dc.format.page101392
dc.format.volume124
dc.identifier.doi10.1016/j.ajcnut.2026.101392
dc.identifier.e-issn1938-3207
dc.identifier.journalThe American journal of clinical nutrition
dc.identifier.pubmedID42269969
dc.identifier.urihttps://hdl.handle.net/20.500.12105/27813
dc.language.isoeng
dc.relation.isreferencedbyPubMed
dc.relation.publisherversion10.1016/j.ajcnut.2026.101392
dc.repisalud.institucionCNIC
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectbiomarkers
dc.subjectbrain health
dc.subjectdiet
dc.subjectenergy metabolism
dc.subjectneuroimaging
dc.subject.meshHumans
dc.subject.meshMiddle Aged
dc.subject.meshFemale
dc.subject.meshMale
dc.subject.meshCross-Sectional Studies
dc.subject.meshProspective Studies
dc.subject.meshLongitudinal Studies
dc.subject.meshBiomarkers
dc.subject.meshPositron-Emission Tomography
dc.titleCirculating palmitoleic acid is associated with cerebral glucose metabolism in healthy middle-aged individuals: results from the Progression of Early Subclinical Atherosclerosis prospective cohort study.
dc.typejournal article
dc.type.hasVersionVoR
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Circulating palmitoleic acid is associated with cerebral_Am J Clin Nutr_2026.pdf
Size:
6.01 MB
Format:
Adobe Portable Document Format